SCHEMBL21612013

SCHEMBL21612013

FC(F)(F)c1cc(NCc2csc(-c3ccc(Oc4ccccc4)cc3)n2)ccn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 3/20 0.61
▸ CYP3A4 P08684 2/20 0.61
▸ ROCK2 O75116 1/20 0.43
▸ GRK2 P25098 1/20 0.43
▸ GAA P10253 2/20 0.42
▸ IDH1 O75874 1/20 0.41
▸ CYP2C9 P11712 2/20 0.40
▸ SREBF2 Q12772 1/20 0.40
▸ RHOC P08134 1/20 0.40
▸ RHOA P61586 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ STAT3 P40763 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ SCN9A Q15858 1/20 0.38
▸ USP1 O94782 2/20 0.38
▸ WDR48 Q8TAF3 2/20 0.38
▸ TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21614728 0.92 CYP2C19 (0.57) CYP2C19CYP3A4ROCK2GRK2GAA
SCHEMBL21612036 0.92 CYP2C19 (0.52) CYP2C19CYP3A4ROCK2GRK2IDH1
SCHEMBL21614717 0.88 TP53 (0.50) CYP2C19CYP3A4CYP2C9SREBF2LMNA
SCHEMBL21614721 0.85 CYP2C19 (0.51) CYP2C19CYP3A4ROCK2GRK2IDH1
SCHEMBL21614715 0.83 CYP2C19 (0.45) CYP2C19CYP3A4IDH1CYP2C9SREBF2
SCHEMBL21611982 0.82 CYP2C19 (0.54) CYP2C19CYP3A4ROCK2GRK2CYP2C9
SCHEMBL21612023 0.82 IDH1 (0.46) CYP2C19CYP3A4ROCK2GRK2IDH1
SCHEMBL21614718 0.82 SYK (0.42) CYP2C19CYP3A4ROCK2GRK2IDH1
SCHEMBL21614660 0.81 CYP2C19 (0.63) CYP2C19CYP3A4CYP2C9CYP1A2SCN9A
SCHEMBL21614677 0.81 CYP2C19 (0.60) CYP2C19CYP3A4CYP2C9CYP1A2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353606-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-11-18 — — US disclosed
EP-3818045-A1 PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-05-12 — — EP disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353606-A1 PqsR INVERSE AGONISTS QRFPR, P2RY11, QARS1 CYP2C19 1824/4885CYP3A4 3080/4885ROCK2 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback